Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

A capacity crunch in the US sterile fill market is driven by two factors: large pharmaceutical companies acquiring CDMO facilities for their own use, and a growing client demand for US-based manufacturing (reshoring). This creates a significant shortage and an opportunity for independent CDMOs with available capacity.

The push for supply chain diversification and reduced reliance on China is not a new phenomenon. The COVID-19 pandemic first exposed the critical risks of single-source dependency. Recent tariff threats are not the origin of this strategic realignment but rather a powerful accelerant, forcing companies to act on plans already in motion.

The biopharma outsourcing sector has proven surprisingly resilient to international tariffs. Instead of absorbing costs, well-funded European companies are bypassing tariffs altogether by investing in and building new production facilities directly on U.S. soil, effectively onshoring their manufacturing.

Companies are moving away from single, hyper-efficient global supply chains. The new strategy involves setting up parallel, regional manufacturing locations (e.g., China plus the US, or China plus Mexico and Vietnam) to create redundancy and mitigate risks from disruptions like pandemics, natural disasters, or geopolitical events.

While US tariff policies aim to bring pharmaceutical production back onshore, the immediate beneficiaries are likely to be contract manufacturers. Building new proprietary facilities is a slow and expensive process, so companies will lean on agile contract partners to quickly diversify their supply chains in the interim.

For final drug product manufacturing, Actuate engaged two separate US-based partners. This parallel track strategy provided crucial redundancy during the COVID pandemic, ensuring that a shutdown or material shortage (e.g., glass vials) at one plant wouldn't derail their clinical programs.

Contrary to expectations, regulatory approvals were not the main challenge in scaling a COVID vaccine during the pandemic. The most significant constraint was the global supply chain for critical imported biomanufacturing components like filters and resins, as every country competed for the same limited resources.

While US and European pharmaceutical production is set to contract in 2026 after a tariff-driven surge, China's is projected to accelerate. This divergence is driven by China's massive, growing domestic market, making its pharma sector resilient to US trade policies aimed at curbing reliance on it.